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PD98059 decreased both basal and TNF-a–stimulated phos-Role of MAP kinase pathways in mediating IL-6 production
phorylation of ERK1,2.in human primary mesangial and proximal tubular cells.
Conclusions. This study provides evidence that both the p38Background. Both interleukin-6 (IL-6) and tumor necrosis
and ERK MAPK pathways are important for the regulation offactor-a (TNF-a) are pleiotropic cytokines that have been im-
the production of IL-6 from the proximal tubular and glomeru-plicated in the development of glomerular and tubular injury
in various forms of immune-mediated renal disease, including lar mesangial regions of the nephron. In response to TNF-a,
glomerulonephritis. Although TNF-a has been shown to stimu- the activation of both pathways leads to IL-6 production. These
late IL-6 production in renal cells in culture, the signaling findings could aid in an understanding of the cellular mecha-
mechanisms that regulate IL-6 production are not fully under- nisms that regulate IL-6 production and could provide insights
stood. The aim of this study was to examine the role of the into possible pharmacological strategies in inflammatory renal
p38 and extracellular signal-regulated kinase (ERK) mitogen- disease.
activated protein kinase (MAPK) pathways in regulating TNF-
a–mediated IL-6 production from both primary human mesan-
gial cells (HMCs) and human proximal tubular (HPT) cells.
Interleukin-6 (IL-6) is a pleiotropic cytokine producedMethods. Primary mesangial and proximal tubular cells were
prepared from nephrectomized human kidney tissue. Cells by a wide variety of cell types in response to many differ-
were treated for 24 hours with TNF-a in the presence and ent stimuli, including IL-1 and tumor necrosis factor-a
absence of the specific p38 and ERK1,2 MAPK inhibitors (TNF-a) [1]. Many of its physiological and pathophysio-SB203580 and PD98059, respectively, either alone or in combi-
logical functions have been well characterized and includenation. IL-6 levels in the cell culture media were measured by
the regulation of immune and inflammatory responses,enzyme-linked immunosorbent assay. MAPK activation was
demonstrated by immunoblot for the active kinase (tyrosine/ acute-phase protein production, bone metabolism, and
threonine phosphorylated) in whole cell extracts using phos- hematopoiesis [2–4]. Within the kidney, elevated levels
pho-specific antibodies. p38 MAPK activity in HPT cells was
of both TNF-a and IL-6 have been demonstrated in bothmeasured using an in vitro immunokinase assay using ATF2
the resident and infiltrating cells in various forms ofas the substrate.
Results. TNF-a (0.1 to 100 ng/ml) stimulated a dose-depen- glomerulonephritis and tubulointerstitial nephritis, and
dent increase in IL-6 production in both renal cell types. The indeed have been suggested to contribute to the patho-
activation of the p38 and the ERK1,2 MAPKs occurred follow- genesis or progression of the disease [5, 6]. An increaseding TNF-a stimulation. The role of these activations in IL-6
production of IL-6 from mesangial and proximal tubularproduction was confirmed by the ability of both inhibitors
epithelial cells has been shown in vitro in response toSB203580 (1 to 30 mm) and PD98059 (0.01 to 10 mm) to inhibit
basal and TNF-a–stimulated IL-6 production in both cell types. many diverse stimuli, including lipopolysaccharide
The addition of both inhibitors in combination caused greater (LPS), TNF-a, and IL-1 [7, 8]. The regulation of IL-6
decreases in IL-6 production compared with either inhibitor
production and its exact function within the inflamedalone. Pretreatment with SB203580 (10 mm) had no effect on
kidney remain to be identified.basal or TNF-a–stimulated phosphorylation of p38 MAPK but
completely abolished TNF-a–stimulated p38 MAPK activity. In other nonrenal cell types, IL-6 production has been
shown to be regulated by the activation of mitogen-
activated protein kinases (MAPKs) [9]. MAPKs consti-Key words: interleukin-6, MAPK, inflammatory renal disease, TNF-a,
cytokines, glomerulonephritis. tute a group of important intracellular mediators of sig-
nal transduction from the cell surface to the nucleus
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phosphorylation and activation of target proteins, includ- Human proximal tubular cell culture
ing transcription factors that can lead to an alteration Human renal cortex was obtained from uninvolved
in gene expression. There are currently three well-char- sections of nephrectomized human kidneys removed be-
acterized mammalian MAPK signaling cascades: (a) cause of renal cell carcinoma. Proximal tubular fragments
the classic p42/44 [extracellular signal-regulated kinase were obtained as described previously [21, 22] using col-
(ERK)] MAPK pathway, which is linked to the regula- lagenase (type II; Sigma, Poole, Dorset, UK) digestion
tion of cell growth and differentiation; (b) the c-jun followed by percoll density gradient centrifugation at
N-terminal kinases (JNKs) or stress-activated protein 20,000 g for 30 minutes at 48C. Proximal tubular frag-
kinases (SAPKs); and (c) the p38-MAPKs. The latter ments were plated at a density of 5 3 104 fragments/ml.
two are involved in the cellular response to environmen- Epithelial colonies were evident after 48 hours of growth.
tal stress [12, 13]. The elucidation of the biological func- The cells were maintained in specially formulated glu-
tion of the different pathways can be aided by the use cose-free 1:1 Dulbecco’s modified Eagle’s medium
of specific inhibitors. These include PD98059, an inhibi- (DMEM)/HAMS F-12 (Promocell, Heidelberg, Ger-
tor of ERK1,2 MAPK (MEK1) activity [14], and many) supplemented with 10% (vol/vol) fetal calf serum
SB203580 [15], an inhibitor of p38 MAPK activity. In (FCS), 2 mm l-glutamine, 10 mm sodium pyruvate, 50
U/ml penicillin, and 50 mg/ml streptomycin. In addition,renal disease, MAPKs have been shown to be activated
the amino acid d-valine was substituted for l-valine toin response to both growth factors and proinflammatory
inhibit the growth of fibroblasts that require l-valine forcytokines in a number of pathological conditions [16–18].
growth [23, 24]. Cells were characterized as proximalIn a rat model of mesangioproliferative glomerulone-
tubular in origin using morphological, immunological,phritis, the activation of the ERK MAPK pathway was
and functional techniques [25, 26].proposed as a putative mechanism for the proliferative
response observed in this disease [19]. In vitro, the activa-
Human mesangial cell isolationtion of MAPKs has been demonstrated in mesangial cells
Human mesangial cells were isolated as previouslyfollowing exposure to both IL-1 and reactive oxygen
described [27, 28]. In brief, glomeruli were isolated fromspecies [20].
minced renal cortex by differential sieving (mesh sizesThe aims of this study were to directly compare the
180, 106, and 75 mm). Glomeruli that collected on thebasal and TNF-a–stimulated IL-6 production in human
lower two sieves were subjected to collagenase (type II;primary mesangial cells (HMCs) and proximal tubular
Sigma) digestion at 378C for 20 minutes. They were then(HPT) cells. The role of MAPK cascades, particularly
plated onto 1% gelatin-coated (Sigma) tissue culturethe p38 and ERK MAPK cascades, in mediating IL-6
flasks, and mesangial cells appeared as outgrowths fromproduction was investigated. We demonstrate that in
the digested glomeruli by day 10 and reached confluenceboth renal cell types, TNF-a induces IL-6 production
by day 30. Cells were maintained in RPMI medium sup-through simultaneous activation of the p38 and ERK
plemented with 10% (vol/vol) FCS and penicillin-strep-MAPK pathways.
tomycin (50 U/ml and 50 mg/ml, respectively) and were
used for experiments between passages 3 and 10. The
identity of the HMCs was confirmed morphologicallyMETHODS
by the display of the characteristic hillock structures inMaterials
the culture and by the use of a series of cell markers
The whole cell p38 and ERK2 antibodies were pur- [27, 28].
chased from Santa Cruz Biotechnology (Heidelberg, Ger-
many). The phospho-specific p38 and phospho-specific Experimental protocol
ERK1,2 antibodies were obtained from New England Confluent HMCs and HPTs were grown in either 24-
BioLabs (Beverly, MA, USA). Activating transcription or 6-multiwell tissue culture plates or 100 mm Petri
factor 2 (ATF2, 1–96) was from Santa Cruz. SB203580 dishes (Falcon, Cowley, Oxford, UK). Prior to drug treat-
and PD98059 were purchased from Calbiochem (La Jolla, ment, cells were serum deprived for 24 hours to render
CA, USA). For the enzyme-linked immunosorbent assay them quiescent. For the determination of IL-6 produc-
(ELISA), both the monoclonal mouse antihuman IL-6 tion using ELISA, cells were treated for 24 hours with
primary antibody and the streptavidin-conjugated horse- TNF-a (0.1 to 100 ng/ml). For MAPK inhibitor experi-
radish peroxidase (HRP) detection reagent were ob- ments, cells were pretreated for one hour with the spe-
tained from Genzyme (West Malling, Kent, UK), and the cific MAPK inhibitors SB203580 and PD98059 either
biotinylated polyclonal goat antihuman IL-6 secondary alone or in combination prior to cytokine exposure. For
antibody came from R&D Systems (Abingdon, Oxon, an analysis of MAPK activation and MAPK activity, cells
UK). All other reageants were of the highest available were treated with 10 ng/ml TNF-a for 15 minutes at 378C
in the presence and absence of the MAPK inhibitors.purity from commercial sources.
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Assay for interleukin-6 preadsorbed to protein A-sepharose for two hours. Im-
munocomplexes were then used to measure p38 MAPKThe wells of a 96-well microtiter plate (NUNC Immu-
activity.noplate, Hereford, UK) were coated with a monoclonal
mouse antihuman IL-6 (1.25 mg/ml) capture antibody p38 Mitogen-activated protein kinase activity assay
overnight at 48C. Culture media from treated cells or
For measurement of p38 MAPK activity, the respec-IL-6 standard were then added to wells and incubated for
tive immunocomplexes were collected by centrifugation,one hour at 378C followed by the addition of secondary
washed four times with a washing buffer (50 mm Tris-antibody (25 ng/ml biotinylated polyclonal goat antihu-
HCl, pH 7.5, 100 mm NaCl, 5 mm EGTA, and 0.5%man IL-6) also for one hour at 378C. Following washing,
Triton X-100) and once with a kinase buffer (20 mmdetection reagent (streptavidin-conjugated HRP) was
HEPES, pH 7.4, 10 mm MgCl2, 1 mm dithiothreitol, andthen added and incubated for 30 minutes at 378C. Sub- 10 mm p-nitrophenylphosphate) and were resuspended
strate solution (phosphate-citrate buffer containing 100 in a final volume of 20 ml of kinase buffer containing
mg/ml 3,39,5,59-tetra-methylbenzidine) was added for 15 200 mg/ml GST-ATF-2, 100 mM ATP, and 10 mCi of
minutes at room temperature, and the reaction was [[g]-32P]ATP. The reaction was initiated by incubation
halted by the addition of 1.8 m H2SO4. The absorbance at 308C and was continued for 10 minutes. Thereafter,
was measured at 450 nm using a Dynatech MR5000 20 ml of 2 3 Laemmli sample buffer were added to
multiwell plate reader. terminate the reaction. Samples were then boiled for
three minutes and subjected to 10% SDS-PAGE. The
Western blot analysis gels were stained in Coomassie Brilliant Blue, dried, and
For Western blot analysis, whole cell extracts were exposed for 24 to 48 hours to Amersham Hyperfilm MP
prepared in 1 3 Laemmli buffer separated on 12% so- at 2708C with intensifying screens. Kinase activity was
dium dodecyl sulfate-polyacrylamide gel electrophoresis visualized and quantitated by densitometry of the ex-
(SDS-PAGE) gels [29] and transferred to a nitrocellulose posed autoradiographic film.
membrane using a semi-dry transfer system. The mem-
Data analysisbranes were then blotted with the appropriate primary
For analysis of the data, confidence intervals wereantibody: antiphospho ERK-1,2, which detects phosphor-
constructed (95, 99, 99.9, and 99.99%), and an unpairedylated tyrosine 204 and threonine 202 of ERK1 and
Student’s t-test was used to test for statistical significance.ERK2; antiphospho p38, which detects p38 when acti-
Where appropriate, an analysis of variance followed byvated by dual phosphorylation at threonine 180 and tyro-
a Dunnett post-test was performed. Results are ex-sine 182; or whole cell p38 and ERK2 antibodies. The
pressed as the mean 6 sem, and a value of P , 0.05 wasprimary antibodies were detected using an anti-rabbit
deemed significant.HRP-conjugated antibody and bands visualized using en-




After treatment cells were washed three times with
Human proximal tubular epithelial cells formedphosphate-buffered saline and lyzed in ice-cold Triton
monolayers that had the typical cobblestone appearance
X-100 lysis buffer (50 mm Tris-HCl, pH 7.5, 100 mm
of epithelial cell monolayers (Fig. 1A). They stained
NaCl, 50 mm NaF, 5 mm ethylenediaminetetraacetic acid positive for the epithelial intermediate filament protein
(EDTA), 40 mm b-glycerophosphate, 200 mm sodium cytokeratin but negative for the endothelial marker Fac-
orthovanadate, 0.1 mm phenylmethylsulfonyl fluoride, 1 tor VIII-related antigen (data not shown). The uptake
mg/ml leupeptin, 1 mm pepstatin, and 1% Triton X-100) of the nonmetabolizable glucose analogue 14C-methyl-
for 25 minutes at 48C. Insoluble material was removed a-D-U-glucopyranoside was significantly reduced when
by centrifugation at 12,000 3 g for 15 minutes at 48C. sodium was replaced by N-methyl-glucamine and in the
The microbicinchoninic acid assay (Pierce) was used to presence of the transport inhibitor 1 mm phlorizin (data
determine protein content using bovine serum albumin not shown), indicating the presence of the proximal tubu-
(BSA) as a standard. Cell extracts were matched for lar Na/hexose cotransport system. These results would
protein content and were precleared with 2 ml of preim- indicate that the cells are predominantly of proximal
mune serum preadsorbed to 50 ml of protein A-sepha- tubular origin [25, 26].
rose–coated beads (Pharmacia, Little Chalfont, Bucks, Glomerular mesangial cells appeared as a homoge-
UK) for one hour at 48C. The precleared supernatants nous population after 30 days in culture. They displayed
were further incubated overnight with 13 ml of a poly- the typical stellate “hill and valley” morphology charac-
teristic of mesangial cells in culture (Fig. 1B). As evi-clonal antibody recognizing p38 MAPK, which had been
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Fig. 1. Phase contrast microscopy of human proximal tubular (A) and
human mesangial cells (B) in culture. Human proximal tubular epithelial
cells displayed the typical epithelial cobblestone-like morphology (A).
Human mesangial cells appeared as elongated cells in multilayers (B).
Magnification (3450).
Fig. 2. Tumor necrosis factor-a (TNF-a)–induced dose-dependent in-
crease in interleukin-6 (IL-6) production from human proximal tubular
(A) and human mesangial (B) cells. Cells were grown to confluencedenced by transmission electron microscopy (data not and treated with TNF-a (0.1 to 100 ng/ml) for 24 hours. Cell culture
shown), the HMCs contained bundles of microfilaments medium was removed and assayed for IL-6 by ELISA, and levels were
expressed as fold over basal concentrations (pg/ml). Each value repre-oriented parallel to the plasma membrane similar to mes-
sents the mean 6 sem of 4 to 11 experiments each performed in dupli-
angial cells in vivo [28]. The cells displayed positive stain- cate. *P , 0.05; **P , 0.01; ***P , 0.001, statistically significant
difference compared with control.ing for vimentin and a-smooth muscle actin and negative
staining for cytokeratin, thus excluding glomerular epi-
thelial contamination (data not shown).
from both proximal tubular (Fig. 2A) and mesangialBasal and TNF-a–stimulated IL-6 production from
(Fig. 2B) cells. For example, 10 ng/ml TNF-a stimulated
human proximal tubular and mesangial cells
4.3 6 0.5-fold (N 5 10) and 4.7 6 0.5-fold (N 5 9) over
Both cell types exhibited basal production of IL-6 with basal IL-6 levels in proximal tubular and mesangial cells,
levels of 23.2 6 4.7 pg/ml (N 5 10) in proximal tubular respectively. There was no further increase in IL-6 pro-
cells and 12.9 6 3.0 pg/ml (N 5 11) in mesangial cells. duction using 100 ng/ml TNF-a. Therefore, for all subse-
Following 24 hours of treatment, TNF-a stimulated dose- quent experiments, cells were treated with 10 ng/ml
TNF-a.dependent (0.1 to 100 ng/ml) increases in IL-6 production
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Fig. 3. Inhibition of basal (A and C ) and
TNF-a (B and D) stimulated IL-6 production
from human proximal tubular (A and B) and
human mesangial (C and D) cells by the spe-
cific p38 mitogen-activated protein kinase
(MAPK) inhibitor SB203580. Cells grown to
confluence were pretreated with SB203580
(1 to 30 mm) for one hour prior to stimulation
with TNF-a (10 ng/ml) for 24 hours. Cell cul-
ture medium was removed and assayed for
IL-6 by ELISA, and levels in the presence of
different inhibitor concentrations were ex-
pressed and compared as fold over basal or
fold over TNF-a–stimulated concentrations
(pg/ml). Each value represents the mean 6
sem of four experiments, each performed in
duplicate. *P , 0.05; **P , 0.01; ***P ,
0.001; statistically significant difference com-
pared with control.
Inhibition by the p38 MAPK inhibitor SB203580 of 182. Whole cell p38 MAPK expression was assessed to
basal and TNF-a–stimulated IL-6 production control for cytokine-induced alterations in the protein
content of the kinase. No changes in whole cell p38The specific p38 MAPK inhibitor SB203580 [15] was
MAPK expression were apparent after any of the treat-used to examine the involvement of this signaling cas-
ments used (lower panels, Fig. 4 A, B) in either cell type.cade in mediating IL-6 production from mesangial and
TNF-a (10 ng/ml) treatment for 15 minutes caused antubular cells. Cells were pretreated with SB203580 (1 to
increase in p38 MAPK phosphorylation in both proximal30 mm) for one hour prior to stimulation with TNF-a
tubular (upper panel, Fig. 4A) and mesangial cells (upper(10 ng/ml) for 24 hours. SB203580 was not toxic to the
panel, Fig. 4B), as evidenced by increased expression ofcells at these concentrations, as evidenced by no losses
the phosphorylated form of the kinase. Pretreatmentin cellular viability (data not shown). Doses of SB203580
with 10 mm SB203580 had no effect on either basal orgreater than 30 mm were, however, toxic to the cells and
TNF-a–stimulated p38 MAPK phosphorylation in eithertherefore could not be used (data not shown). SB203580
cell types (upper panels, Fig. 4 A, B).(1 to 30 mm) caused dose-dependent decreases in both
basal (Fig. 3 A, C) and TNF-a–stimulated (Fig. 3 B, D)
Inhibition of tumor necrosis factor-a–stimulated p38IL-6 production from both proximal tubular (Fig. 3 A,
MAP kinase activity by SB203580B) and mesangial cells (Fig. 3 C, D).
The effect of SB203580 on the downstream kinase
Basal and tumor necrosis factor-a–stimulated p38 activity of p38 MAPK was then measured in order to
MAPK phosphorylation (activation) was not inhibited establish the stage in the kinase cascade that the com-
by SB203580 pounds act to inhibit IL-6 production in renal cells. p38
MAPK activity in human proximal tubular cells was mea-The activation of p38 MAPK is normally characterized
sured using an in vitro immunokinase assay using ATF2by dual phosphorylation on specific tyrosine and threo-
as the substrate for the reaction. TNF-a (10 ng/ml) in-nine residues. p38 MAPK phosphorylation (activation)
duced a large increase in kinase activity in proximalin this study was investigated using a phospho-specific
tubular epithelial cells. This was completely abolishedp38 MAPK antibody, which detects p38 when activated
by dual phosphorylation at threonine 180 and tyrosine by prior treatment with 10 mm SB203580 (Fig. 5). p38
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Fig. 4. TNF-a–induced stimulation of p38
MAPK phosphorylation (activation) in hu-
man proximal tubular (A) and human mesan-
gial (B) cells, which were not affected by
SB203580. Confluent cells, serum deprived for
24 hours, were pretreated with SB203580 (10
mm) for one hour followed by TNF-a (10
ng/ml) stimulation for 15 minutes. Whole cell
extracts subjected to SDS-PAGE were probed
using Western blotting and antibodies di-
rected against the phosphorylated or whole
cell p38 MAPK. The bands were visualized
by ECL. Phosphorylated p38 MAPK is shown
in the upper panels, and whole cell p38 MAPK
is shown in the lower panels. Representative
blots from one of three separate experiments
are shown.
than 10 mm were, however, toxic to the cells and therefore
could not be used. PD98059 (0.01 to 10 mm) caused dose-
dependent decreases in both basal (Fig. 6 A, C) and
TNF-a stimulated (Fig. 6 B, D) IL-6 production from
both proximal tubular (Fig. 6 A, B) and mesangial cells
(Fig. 6 C, D). TNF-a–stimulated IL-6 levels were inhib-
ited by similar amounts in both cell types (Fig. 6 B, D).Fig. 5. Inhibition by SB203580 of the TNF-a–stimulated increase in
p38 MAPK activity in human proximal tubular epithelial cells. Conflu-
ent cells, serum deprived for 24 hours were pretreated with SB203580 Basal and TNF-a stimulated ERK1,2 MAPK
(10 mm) for one hour followed by TNF-a (10 ng/ml) stimulation for 15 phosphorylation (activation) was inhibited
minutes. p38 MAPK was immunoprecipitated from whole cell extracts,
by PD98059and activity was measured as the incorporation of a radiolabeled phos-
phate into an artificial substrate ATF2. The incorporation was visualized The activation of ERK1,2 MAPK is also characterized
by autoradiography after SDS-PAGE.
by dual phosphorylation. The phospho-specific antibody
“antiphospho ERK-1,2,” which detects phosphorylated
tyrosine 204 and threonine 202 of ERK1 and ERK2, was
used to detect ERK phosphorylation (activation) in this
MAPK activity could not be detected in mesangial cells system. Whole cell ERK2 expression was assessed to
at the level of sensitivity used in this kinase assay. control for cytokine-induced alterations in the protein
content of the kinase. No changes in whole cell ERK2
Inhibition of basal and TNF-a stimulated IL-6 kinase expression were apparent after any of the treat-
production by the MEK1 inhibitor PD98059 ments in either cell type used (lower panels, Fig. 7 A,
The specific MEK1 inhibitor PD98059 [14] was used B). Basal levels of ERK1,2 MAPK phosphorylation were
to assess the involvement of the ERK1,2 pathway in increased after treatment with TNF-a (10 ng/ml) for 15
mediating IL-6 production from human renal cells. Cells minutes in both proximal and mesangial cells (upper
were pretreated with PD98059 (0.01 to 10 mm) for one panel, Fig. 7B). The TNF-a–induced ERK1 phosphory-
hour prior to stimulation with TNF-a (10 ng/ml) for lation appeared to be greater than that of ERK2.
24 hours. PD98059 was not toxic to the cells at these PD98059 (10 mm) reduced both basal and TNF-a–
concentrations, as evidenced by no losses in cellular via- stimulated ERK1,2 MAPK phosphorylation in both cell
types (upper panels, Fig. 7 A, B).bility (data not shown). Doses of PD98059 of greater
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Fig. 6. Inhibition of basal (A and C ) and
TNF-a (B and D)–stimulated IL-6 production
from human proximal tubular (A and B) and
mesangial (C and D) cells by the specific
MEK1 inhibitor PD98059. Cells grown to con-
fluence were pretreated with PD98059 (0.01
to 10 mm) for one hour prior to stimulation
with TNF-a (10 ng/ml) for 24 hours. Cell cul-
ture medium was removed and assayed for
IL-6 by ELISA, and levels in the presence of
different inhibitor concentrations were ex-
pressed and compared as fold over basal or
fold over TNF-a–stimulated concentrations
(pg/ml). Each value represents the mean 6
sem of four to eight experiments each per-
formed in duplicate. *P , 0.05; **P , 0.01;
***P , 0.001; statistically significant differ-
ence compared to control.
Further inhibition of basal and TNF-a–stimulated IL-6 The pathophysiology of many experimental models
of glomerulonephritis are consistent with the associatedproduction using a combination of SB203580
and PD98059 overproduction of cytokines in both the glomerular and
tubulointerstitial regions [30–32]. Tubulointerstitial fi-Finally, the effects of a combination of both MAPK
brosis has been proposed as a final common pathwayinhibitors on IL-6 production in mesangial and proximal
for progressive renal injury in most renal diseases, andtubular cells were assessed. Cells were pretreated with
the level of tubulointerstitial fibrosis correlates closelySB203580 (10 mm) or PD98059 (10 mm) either alone or
with the degree of chronic renal dysfunction in thesein combination for one hour prior to stimulation with
settings [33]. Tubular epithelial cells once consideredTNF-a (10 ng/ml) for 24 hours. Cotreatment of cells with
passive bystanders in the disease process have since beenboth inhibitors caused significant decreases in both basal
shown to be actively involved and are indeed a rich(Fig. 8 A, C), and TNF-a stimulated (Fig. 8 B, D) IL-6
source of cytokines, chemokines, and other inflammatoryproduction from proximal tubular (Fig. 8 A, B) and mes-
mediators [7, 34–36].angial cells (Fig. 8 C, D) as compared with cells treated
Tumor necrosis factor-a expression has been found towith the relevant inhibitor alone.
be increased in vivo in various inflammatory renal dis-
eases and in vitro in both mesangial and proximal tubular
DISCUSSION cells [37, 38]. TNF-a has been reported as a potent stimu-
lator of IL-6 production [9]. Both glomerular mesangialIn this study, we demonstrated that primary human
mesangial and proximal tubular cells produce similar and tubular epithelial cells have been shown to express
and secrete IL-6 [7, 8, 39]. IL-6 has been shown to beamounts of basal IL-6 and respond to TNF-a with similar
increases in IL-6 production. Furthermore, the TNF-a produced in mesangial cells in response to a number of
stimuli, including immune complexes, IgA, and a numbermediated IL-6 production involved the activation of the
p38 and ERK MAPK pathways. These in vitro systems of proinflammatory cytokines, where it is thought to act
as an autocrine growth factor stimulating mesangial cellof human cells provide models to explore mechanisms
of cytokine-mediated events relevant to human renal hyperproliferation [40–42]. A recent study suggested
that apoptotic monocytes are also capable of inducingdisease.
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angial and proximal tubular regions. Initially, we estab-
lished that the basal production of IL-6 occurred in pri-
mary mesangial and proximal tubular cells and that the
levels of IL-6 produced from both cell types were similar.
Then we established that TNF-a (0.1 to 100 ng/ml) treat-
ment for 24 hours stimulated a dose-dependent increase
in IL-6 production in both glomerular mesangial and
proximal tubular epithelial cells. TNF-a appeared to
cause a similar level of stimulation of IL-6 production
from both cell types.
Mitogen-activated protein kinases are a crucial part
of cellular signal transduction machinery and play major
roles in cell growth, differentiation, and transformation
[10]. The use of the specific inhibitors of the p38 and
ERK1,2 MAPK pathways SB203580 and PD98059, re-
spectively, has facilitated investigations of these path-
ways. In these studies, the activation of both the p38
and the ERK1,2 MAPKs above basal levels occurred
following TNF-a stimulation in both cell types. The bio-
logical significance of this activation was confirmed by
the ability of the inhibitors SB203580 (1 to 30 mm) and
Fig. 7. TNF-a–induced stimulation of ERK1,2 phosphorylation (acti- PD98059 (0.01 to 10 mm) to inhibit basal and TNF-a–
vation) in human proximal tubular (A) and mesangial (B) cells, which stimulated IL-6 production in both cell types. Pretreat-were inhibited by the specific MEK1 inhibitor PD98059. Confluent cells,
ment with SB203580 (10 mM) had no effect on basal orserum deprived for 24 hours, were pretreated with PD98059 (10 mm) for
1 hour followed by TNF-a (10 ng/ml) stimulation for 15 minutes. Whole TNF-a–stimulated activation (phosphorylation) of p38
cell extracts subjected to SDS-PAGE were probed using Western blot- MAPK but completely abolished TNF-a–stimulated p38ting and antibodies directed against the phosphorylated form of ERK1,2
MAPK activity. PD98059 decreased both basal and TNF-MAPK or whole cell ERK2. The bands were visualized by ECL. Phos-
phorylated ERK1,2 MAPK is shown in the upper panels, and whole a–stimulated ERK1,2 phosphorylation, indicating that
cell ERK2 is shown in the lower panels. Representative blots from one both inhibitors reduce IL-6 production by acting at dif-of three separate experiments are shown.
ferent stages in their respective cascades. The level of
inhibition observed appeared to depend on agonist
(TNF-a) stimulation. We confirmed the specificity of the
inhibitors by the fact that neither inhibitor had any effectan exaggerated mesangial IL-6 production [43]. Urinary
IL-6 production has been correlated to disease progres- on the activation of the other respective pathway (data
not shown). The doses responsible for the inhibitionsion, and it has been shown that the level of urinary IL-6
could be influenced not only by mesangial cell prolifera- of IL-6 production by SB203580 and PD98059 closely
corresponded to those required for inhibition of p38tion but also by renal tubular dysfunction [44]. However,
the exact functional role of IL-6 in renal disease is contro- MAPK activity and ERK1,2 phosphorylation, respec-
tively, confirming that MAPK activation was involvedversial. In some studies, the degree of mesangial hyper-
proliferation, tubular atrophy, and intensity of interstitial in TNF-a–induced IL-6 synthesis in renal cells. A combi-
nation of both inhibitors caused significantly greater de-infiltrates have been correlated to the renal expression
and urine concentration of IL-6 [45, 46]. However, more creases in IL-6 production as compared with either inhib-
itor alone, clearly indicating that both signaling pathwaysrecent studies have demonstrated that IL-6 may, in fact,
have anti-inflammatory effects in renal disease and does are involved in regulating IL-6 production in renal cells.
It is interesting to note that a total abrogation of TNF-not induce mesangial cell proliferation [47, 48]. Regard-
less of the exact functional role, IL-6 production has been a–induced IL-6 production was not achieved even in
the presence of both inhibitors, suggesting that othertightly correlated to renal disease progression. However,
the mechanisms and signaling events that regulate IL-6 additional signaling pathways may be involved in the
transduction of the TNF-a signal.production in renal cells have not been established.
To provide more insight into the roles of IL-6 and Although, to our knowledge, these studies are the first
demonstration of the involvement of both the p38 andTNF-a in renal disease, it is necessary to provide models
relevant to the human situation where mechanisms and ERK MAPK pathways in IL-6 production from HMCs
and tubular cells, other studies have been reported in non-signaling events can be explored. Therefore, in this study,
we focused on both basal and TNF-a–stimulated IL-6 renal cells. In osteoblast-like MC3T3-E1 cells, PD98059
was reported to bring about a dose-dependent decreaseproduction in primary renal cells representing the mes-
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Fig. 8. Further inhibition of basal (A and C )
and TNF-a (B and D)–stimulated IL-6 produc-
tion from human proximal tubular (A and B)
and human mesangial (C and D) cells by a com-
bination of the MAPK inhibitors SB203580 and
PD98059. Cells grown to confluence were pre-
treated with PD98059 (10 mm) and SB203580
(10 mm) for one hour prior to stimulation with
TNF-a (10 ng/ml) for 24 hours. Cell culture
medium was removed and assayed for IL-6
by ELISA, and levels in the presence of inhibi-
tors were expressed and compared as fold over
basal or fold over TNF-a–stimulated concen-
trations (pg/ml). Each value represents the
mean 6 sem of four to eight experiments each
performed in duplicate. *P , 0.05; **P , 0.01;
statistically significant difference compared to
each inhibitor added alone.
in sphingosine 1-phosphate–stimulated IL-6 production mokines. In addition to IL-6, TNF-a also induces the
expression of a number of other inflammatory mediators[49]. Sphingosine 1-phosphate is a downstream mediator
of TNF-a–induced signal transduction [50]. In the implicated in renal disease, for example, adhesion mole-
cules such as intercellular adhesion molecule-1 (ICAM-1)MC3T3-E1 cells, PD98059 (10 mm) failed to inhibit IL-6
production by more than 50%, which is similar to that and vascular cell adhesion molecule-1 (VCAM-1) and
chemokines such as IL-8 [54]. However, TNF-a appearsobserved in mesangial and tubular cells in our studies.
In HeLa and L-929 cells, a complete inhibition of TNF- to differentially regulate the expression of these mole-
cules. For example, in cultured mouse sertoli cells, it hasa–stimulated IL-6 expression has been shown with
SB203580 (10 mm) [9]. This is in contrast to our findings been shown that in response to TNF-a, the activation
of p38 MAPK leads to IL-6 production, whereas ICAM-1in mesangial and tubular cells, where only approximately
50% inhibition was found with a similar dose of and VCAM-1 are induced by activation of the JNK path-
way [53]. In addition, in vascular endothelial cells, theSB203580. In human fibroblasts and endothelial cells,
Ridley et al showed a 60 and 75% inhibition of IL- activation of the p38 MAPK pathway was shown to be
important in IL-1–stimulated IL-6 production but was1–stimulated IL-6 production with SB203580 (10 mm)
[51]. These values are more similar to the levels of inhibi- not involved in the production of IL-8 [51].
The specific roles of the p38 and ERK MAPK path-tion observed in these studies in mesangial and proximal
tubular cells. In these studies, IL-6 production in human ways in mediating gene expression and the level at which
they mediate this expression are still relatively unre-mesangial and proximal tubular cells was inhibited by
both PD98059 and SB203580, implicating the involve- solved [55]. SB203580 has been shown to inhibit LPS-
stimulated IL-1 and TNF-a expression [56] and also IL-1ment of both pathways in IL-6 production. In Kupffer
cells, both pathways have also been shown to mediate induced IL-6 [57] expression at the translational level.
However, the inhibition of TNF-a–induced IL-6 expres-IL-6 production [52]. However, in Sertoli cells, IL-6 pro-
duction was inhibited by SB203580 but not by PD98059, sion appears to be at the transcriptional level. Nuclear
factor-kB (NF-kB) is the main transcriptional activatorindicating that only the p38 MAPK pathway plays a role
in these cells [53]. Clearly, the extent of SB203580 and for both TNF-a and IL-1–induced IL-6 gene induction.
NF-kB exists typically as a dimer between p50 and thePD98059 mediated the inhibition of IL-6 production is
very much cell-type specific. transactivating subunit p65 [58]. A recent study used
site-directed mutagenesis of the IL-6 promoter and re-The MAPK pathways have also been implicated in
TNF-a–mediated expression of other cytokines and che- ported a necessity for NF-kB transcriptional activity in
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Fig. 9. Proposed hypothesis for the regula-
tion of TNF-a–induced IL-6 production in re-
nal cells.
mediating TNF-a–stimulated IL-6 gene transcription mechanisms that regulate IL-6 production from both the
glomerular and tubulointerstitial regions of the nephron.[59]. The MAPK inhibitors SB203580 and PD98059 were
shown to have a direct repressive effect on the transacti-
vation potential of the p65 subunit, suggesting that both ACKNOWLEDGMENTS
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